Trevi Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Trevi Therapeutics
TRVI Stock  USD 11.10  0.46  4.32%   
Trevi Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Trevi Therapeutics' valuation are provided below:
Market Capitalization
1.4 B
Earnings Share
(0.37)
We have found one hundred twenty available fundamental trend indicators for Trevi Therapeutics, which can be analyzed and compared to other ratios and to its competition. Traders should compare all of Trevi Therapeutics current fundamentals against the fundamentals between 2010 and 2026 to make sure the company is sustainable this year. The Trevi Therapeutics' current Market Cap is estimated to increase to about 393.4 M. The Trevi Therapeutics' current Enterprise Value is estimated to increase to about 362.1 M
Check Trevi Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Trevi Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 4.3 M, Discontinued Operations of 0.0 or Depreciation And Amortization of 177.5 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 3.95. Trevi financial statements analysis is a perfect complement when working with Trevi Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Trevi Stock
Check out the analysis of Trevi Therapeutics Correlation against competitors.
For more detail on how to invest in Trevi Stock please use our How to Invest in Trevi Therapeutics guide.

Trevi Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets133.9 M127.5 M48.9 M
Slightly volatile
Short and Long Term Debt Total882.4 K928.8 K12 M
Slightly volatile
Other Current Liabilities8.2 M7.8 M3.8 M
Slightly volatile
Total Current Liabilities7.4 M9.5 M13.1 M
Slightly volatile
Other Liabilities2.6 K2.7 K197.9 K
Slightly volatile
Property Plant And Equipment Net1.5 M1.4 M413 K
Slightly volatile
Accounts Payable2 M3.9 M1.5 M
Slightly volatile
Cash32.5 M39.2 M22.8 M
Slightly volatile
Non Current Assets Total897.2 K1.7 M590.2 K
Slightly volatile
Non Currrent Assets Other288.6 K218.7 K225.1 K
Slightly volatile
Cash And Short Term Investments130 M123.8 M47.1 M
Slightly volatile
Net Receivables642.4 K611.8 K252.5 K
Slightly volatile
Common Stock Shares Outstanding122 M116.2 M40.7 M
Slightly volatile
Long Term Debt Total2.3 M2.5 M4.7 M
Pretty Stable
Liabilities And Stockholders Equity133.9 M127.5 M48.9 M
Slightly volatile
Non Current Liabilities Total638.7 K672.3 K4 M
Slightly volatile
Other Current Assets1.5 M1.5 M928.7 K
Slightly volatile
Total Liabilities10.4 M10.1 M17.2 M
Slightly volatile
Total Current Assets132.1 M125.8 M48.3 M
Slightly volatile
Common Stock113.5 K108.1 K37.8 K
Slightly volatile
Property Plant Equipment201.5 K195.5 K120.5 K
Slightly volatile
Property Plant And Equipment Gross1.8 M1.7 M493.6 K
Slightly volatile
Non Current Liabilities Other4.3 K4.5 K180.9 K
Slightly volatile
Net Working Capital60.7 M113.8 M42.4 M
Slightly volatile
Capital Stock61.1 K108.1 K80.4 K
Slightly volatile
Capital Surpluse242.2 M365.2 M220 M
Slightly volatile
Capital Lease Obligations1.2 M1.2 M517.1 K
Slightly volatile
Current Deferred Revenue3 M3.4 M3.7 M
Slightly volatile

Trevi Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income4.3 M4.1 M2.2 M
Pretty Stable
Depreciation And Amortization177.5 K169.1 K50 K
Slightly volatile
Selling General Administrative8.3 M14 M5.9 M
Slightly volatile
Selling And Marketing Expenses185.3 K330.1 K186 K
Slightly volatile
Other Operating Expenses62.2 M59.3 M24.4 M
Slightly volatile
Research Development47.5 M45.3 M18.2 M
Slightly volatile
Total Operating Expenses62.2 M59.3 M24.4 M
Slightly volatile
Reconciled Depreciation177.5 K169.1 K48.9 K
Slightly volatile

Trevi Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation4.3 M4.1 M1.4 M
Slightly volatile
Begin Period Cash Flow28.4 M37.3 M21.4 M
Slightly volatile
Depreciation177.5 K169.1 K50 K
Slightly volatile
Capital Expenditures38.2 K40.2 K51.3 K
Slightly volatile
End Period Cash Flow31.3 M39.2 M22.1 M
Slightly volatile
Change To Netincome2.2 M2.7 M1.4 M
Slightly volatile
Issuance Of Capital Stock44.1 M70.3 M28.2 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation0.260.272.5329
Slightly volatile
Inventory Turnover0.01320.01480.0162
Slightly volatile
Days Of Inventory On Hand17.7 K19.9 K21.8 K
Slightly volatile
Payables Turnover0.0190.0210.0188
Slightly volatile
Cash Per Share1.951.221.3072
Slightly volatile
Days Payables Outstanding24.1 K18 K25.9 K
Slightly volatile
Income Quality0.710.720.911
Slightly volatile
Current Ratio6.039.375.0455
Slightly volatile
Capex Per Share4.0E-44.0E-40.0023
Very volatile
Interest Debt Per Share0.01120.01180.7309
Slightly volatile
Debt To Assets0.01020.01071.1473
Slightly volatile
Operating Cycle17.7 K19.9 K21.8 K
Slightly volatile
Days Of Payables Outstanding24.1 K18 K25.9 K
Slightly volatile
Ebt Per Ebit1.21.071.1623
Slightly volatile
Effective Tax Rate7.0E-47.0E-40.0011
Very volatile
Total Debt To Capitalization0.01120.01182.0109
Slightly volatile
Quick Ratio5.999.375.012
Slightly volatile
Net Income Per E B T0.80.90.9813
Slightly volatile
Cash Ratio5.093.733.1138
Slightly volatile
Days Of Inventory Outstanding17.7 K19.9 K21.8 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.11.151.017
Slightly volatile
Debt Ratio0.01020.01071.1473
Slightly volatile

Trevi Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap393.4 M374.7 M153.1 M
Slightly volatile

Trevi Fundamental Market Drivers

Trevi Upcoming Events

21st of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
21st of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Trevi Therapeutics Financial Statements

Investors use fundamental indicators, such as Trevi Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Trevi Therapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Current Deferred Revenue3.4 M3 M
Cost Of Revenue169.1 K177.5 K

Currently Active Assets on Macroaxis

FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill
CSANCosan SA ADR
RKTRocket Companies
When determining whether Trevi Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Trevi Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Trevi Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Trevi Therapeutics Stock:
How To Invest In Trevi
Details
Is Trevi Stock a good investment?
Details
What is Trevi Therapeutics' Net Worth?
Details
Largest Pharmaceuticals Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Trevi Therapeutics Correlation against competitors.
For more detail on how to invest in Trevi Stock please use our How to Invest in Trevi Therapeutics guide.
You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is there potential for Pharmaceuticals market expansion? Will Trevi introduce new products? Factors like these will boost the valuation of Trevi Therapeutics. If investors know Trevi will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Trevi Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.37)
Return On Assets
(0.24)
Return On Equity
(0.37)
Understanding Trevi Therapeutics requires distinguishing between market price and book value, where the latter reflects Trevi's accounting equity. The concept of intrinsic value - what Trevi Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Trevi Therapeutics' price substantially above or below its fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Trevi Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Trevi Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Trevi Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY